Clinical Trials on Advanced Non-squamous Non-small Cell Lung Cancer in Italy

Total 666 results

Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
National Cancer Institute, Naples

Active, not recruiting

STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study (STAD-1)

Small Cell Lung Cancer

Italy
Seagen Inc.

Recruiting

A Study of SGN-PDL1V in Advanced Solid Tumors

Melanoma | Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Ovarian Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Neoplasms | Esophageal Squamous Cell Carcinoma

United States, Spain, Italy, Canada, United Kingdom, France, Belgium, Germany, Netherlands
Fondazione IRCCS Istituto Nazionale dei Tumori,...
University of Campania "Luigi Vanvitelli"; Istituti Ospitalieri di Cremona; Istituto... and other collaborators

Recruiting

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Cancer | NSCLC | Lung Cancer | Adenocarcinoma of Lung | Squamous Cell Lung Cancer

Italy
Celgene

Active, not recruiting

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Small Cell Lung Carcinoma

France, Italy, Spain
HiFiBiO Therapeutics

Recruiting

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Non Small Cell Lung Cancer

Spain, United States, Italy
Eli Lilly and Company

Active, not recruiting

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (Balise)

Carcinoma, Non-Small-Cell Lung

Spain, Taiwan, United Kingdom, France, Germany, Netherlands, Korea, Republic of, Italy, Denmark
AstraZeneca

Active, not recruiting

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)

Extensive-stage Small Cell Lung Cancer

Canada, Germany, Italy, Czechia, Turkey, Bulgaria
Janssen Research & Development, LLC

Recruiting

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2)

Carcinoma, Non-Small-Cell Lung

Taiwan, United States, Korea, Republic of, Germany, France, China, Japan, Italy, Spain, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Melanoma | Pancreatic Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Cancer | Esophageal Squamous Cell Cancer | BRAF Mutant Colorectal Cancer | Cervical Squamous Cell Cancer | Lung Squamous Cell Cancer

Canada, Italy, Spain, Germany, Netherlands, United States, France
Amgen

Recruiting

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Taiwan, Switzerland, Spain, Canada, Israel, Germany, France, Belgium, Australia, Japan, Italy, Denmark
Boehringer Ingelheim

Completed

LUME BioNIS: a Biomarker Study in Patients With NSCLC

Carcinoma, Non-Small-Cell Lung

Spain, Sweden, Belgium, United Kingdom, Austria, Germany, Denmark, Greece, Hungary, Italy, Netherlands, Lithuania, Luxembourg
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc.

Recruiting

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT)

NSCLC Stage IV | KRAS P.G12C

Ireland, Italy, France, Spain, Belgium, United Kingdom
Eli Lilly and Company

Completed

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (Chime)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Spain, Belgium, France, United Kingdom, Netherlands, Italy, Israel, Korea, Republic of
GlaxoSmithKline

Completed

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome (SCOT)

Lung Cancer, Small Cell

Spain, France, Netherlands, Korea, Republic of, Greece, Slovenia, Italy, Czech Republic, Germany, Austria, Hungary, Poland, Estonia, Lithuania
Takeda

Active, not recruiting

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, Taiwan, Japan, China, Italy, Germany, United Kingdom, Puerto Rico
Boehringer Ingelheim

Completed

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Taiwan, Thailand, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

Netherlands, Belgium, United States, Australia, Greece, Italy, Canada, Japan, Poland, Romania, Spain
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, China, Germany, United States, Brazil, Italy, Spain, France, Canada, Japan, Poland, Turkey, United Kingdom
Eli Lilly and Company

Terminated

Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

Italy, Poland, United Kingdom, Spain
Spectrum Pharmaceuticals, Inc

Terminated

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NSCLC

United States, Canada, Netherlands, Belgium, Israel, Spain, France, Italy
University of Roma La Sapienza

Available

Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer

Cancer | Pancreas | Locally Advanced Pancreatic Cancer | Non-invasive Treatment

Italy
Eli Lilly and Company
AstraZeneca

Completed

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Hepatocellular Carcinoma | Gastric Cancer | Non-Small Cell Lung Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Spain, Korea, Republic of, Taiwan, Germany, Italy, France, Israel
Hoffmann-La Roche
Exelixis

Active, not recruiting

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01)

Carcinoma, Non-Small-Cell Lung

United States, France, Belgium, United Kingdom, Australia, Korea, Republic of, Austria, Italy, Portugal, Spain, Poland, Japan, Germany, Greece, Russian Federation
Hoffmann-La Roche
Jazz Pharmaceuticals

Active, not recruiting

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Small-Cell Lung Cancer

United States, Belgium, Italy, Spain, Turkey, United Kingdom, Korea, Republic of, Germany, Mexico, Hungary, Taiwan, Greece, Poland
Pfizer

Terminated

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

United States, Canada, Belgium, Italy, Spain, United Kingdom, Korea, Republic of, Netherlands, Poland, Portugal, Turkey, Taiwan, Germany, Hungary, Brazil, Hong Kong, Singapore, South Africa, China, Austria, Czech Republic, India, Is... and more
Amgen

Active, not recruiting

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

Relapsed/Refractory Small Cell Lung Cancer

United States, Belgium, Italy, Spain, Portugal, Austria, Greece, Korea, Republic of, Denmark, Netherlands, Germany, France, Taiwan, Japan, United Kingdom, Poland, Switzerland, Singapore
Boehringer Ingelheim

Completed

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Carcinoma, Non-Small-Cell Lung

Spain, Israel, Italy, Austria, Czechia, Greece, Australia, Poland, Hungary, Portugal, Russian Federation
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL)

Carcinoma, Non-Small-Cell Lung

Italy, Netherlands, Argentina, Brazil, China, Denmark, Greece, Panama, Spain, United Arab Emirates, United Kingdom, Mexico, Poland, Peru, Philippines, Costa Rica, Malaysia, Morocco, Latvia, Lebanon, Sweden, Slovenia, Colombia, Guatemala
Boehringer Ingelheim

Completed

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Austria, Germany, Spain, China, Taiwan, Argentina, Australia, Belgium, Brazil, Finland, France, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Russian Federation, Ukraine, United Kingdom
National Cancer Institute, Naples

Completed

G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients (G-Step)

Small Cell Lung Cancer

Italy
AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
Boehringer Ingelheim

Completed

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Bulgaria, Serbia, United Kingdom, United States, Korea, Republic of, Malaysia, Vietnam, Poland, Egypt, Hungary, Ukraine, Brazil, Turkey, Japan, Portugal, Thailand, Philippines, Russian Federation, Italy, Mexico, Greece, Croatia, Chi... and more
Celgene

Completed

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

Belgium, United Kingdom, Netherlands, Italy, Poland
Amgen

Recruiting

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)

Small Cell Lung Cancer (SCLC)

China, United States, Australia, Netherlands, Taiwan, Spain, Canada, Korea, Republic of, Turkey, Israel, Austria, Japan, France, United Kingdom, Germany, Belgium, Denmark, Czechia, Switzerland, Italy, Hungary, Ireland, Argentina, Brazil, Malays... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

Carcinoma, Non-Small-Cell Lung

United States, France, Canada, China, Israel, Belgium, United Kingdom, Italy, Argentina, Japan, Taiwan, Thailand, Korea, Republic of, Malaysia, Poland, Australia, Spain, Netherlands, Hungary, Turkey, Germany, India, Brazil, Russian Federation and more
Pfizer

Terminated

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Australia, United States, Hungary, Germany, Italy, Korea, Republic of, Spain, Sweden, Mexico, South Africa, Taiwan, Belgium, Canada, China, Cyprus, Czech Republic, France, Greece, Hong Kong, India, Israel, Netherlands, Poland, Portugal, Switzerlan... and more
PharmaMar

Completed

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (ATLANTIS)

Small-cell Lung Cancer

France, United States, Germany, Spain, Belgium, Lebanon, United Kingdom, Italy, Netherlands, Brazil, Portugal, Greece, Argentina, Austria, Bulgaria, Canada, Czechia, Hungary, Poland, Romania
Bristol-Myers Squibb

Active, not recruiting

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Russian Federation, Belgium, United States, Australia, Argentina, Brazil, Canada, China, Czechia, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Taiwan, United Kingdom
Alaunos Therapeutics

Unknown

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

Extensive-Stage Small Cell Lung Cancer

United States, Canada, Taiwan, Israel, Italy, Australia, France, Hungary, Poland, Russian Federation, United Kingdom
PharmaMar

Recruiting

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Relapsed Small Cell Lung Cancer

United States, Spain, Japan, Korea, Republic of, United Kingdom, Israel, France, Taiwan, Germany, Australia, Belgium, Georgia, Italy, Switzerland, Denmark, Hungary, Poland, Romania, Canada, Brazil, Bulgaria, Austria, Chile, Turkey
Merck Sharp & Dohme LLC

Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

In Escalation: All Patients With Solid Tumors and Lymphoma | In Expansion: Melanoma, Non-small Cell Lung Cancer

United States, Italy, Taiwan, Belgium, Spain, Germany, Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

Carcinoma, Non-Small-Cell Lung

Canada, Germany, Italy, China, Belgium, United States, Taiwan, Israel, United Kingdom, Sweden, Japan, Poland, Korea, Republic of, Malaysia, Netherlands, Spain, Turkey, France, India, Mexico, Argentina, Brazil, Portugal, Russian Federation and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Germany, Japan, China, Israel, Belgium, Italy, France, Taiwan, Thailand, Korea, Republic of, Malaysia, Spain, Hungary, Turkey, Portugal, India, Poland, Australia, Russian Federation, Mexico, Brazil, Puerto Rico, U... and more
Hoffmann-La Roche

Active, not recruiting

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib (ReAlec)

NSCLC

Belgium, Australia, China, Croatia, Finland, Turkey, Italy, Israel, Serbia, Austria, Romania, Peru, Lithuania, Colombia, Portugal, Czechia, Cuba, Russian Federation, Bulgaria, Vietnam, Uruguay, United Arab Emirates, Argentina, Chile, Pa...
Seagen Inc.

Terminated

A Study of SGN-CD228A in Advanced Solid Tumors

Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Cutaneous Melanoma | Pleural Mesothelioma | HER2 Negative Breast Neoplasms

United States, Spain, France, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150)

Carcinoma, Non-Small-Cell Lung

United States, Spain, France, Belgium, Australia, Germany, Argentina, Japan, Brazil, Italy, Singapore, Russian Federation, Taiwan, Netherlands, Peru, Chile, Latvia, Ukraine, Mexico, Lithuania, Slovakia, Bulgaria, Portugal, Austria, Swit... and more

Clinical Trials on Advanced Non-squamous Non-small Cell Lung Cancer in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations